Surgery Endorsement Maintenance 2010 Steering Committee May 4- May 5, 2011

Embassy Suites DC Convention Center 900 10th Street, NW Washington, DC 202-739-2001 – Embassy Suites 202-783-1300 – NQF

Please use the following information to access the conference call line:

Dial-in Number: 1-888-632-5006 Conference ID: 1586816 Event Title: Surgery Endorsement Maintenance Committee Meeting

FINAL AGENDA

<u>Day 1 – May 4</u>

9:00 am	Welcome and Introductions
	Helen Burstin, MD, MPH, Senior Vice President of Performance Measures
	Arden M. Morris, MD, MPH, Co-Chair
	David Torchiana, MD, Co-Chair
9:10 am	Expectations and Process for the Meeting
	Dr. Morris
	Dr. Torchiana
9:20 am	Recap of Work to Date
	Melinda Murphy, RN, MS, Senior Director
	Alexis Forman, MPH, Project Manager
9:25 am	Phase I Measure Follow-Up
	• Measure Developer Follow-Up of Measure and Steering Committee
	Recommendation for Endorsement
	• 0300: Cardiac patients with controlled 6 am postoperative serum
	glucose
	Steering Committee Recommendation for Endorsement
	• 0114: Risk-adjusted post-operative renal failure
	• 0115: Risk-adjusted surgical re-exploration
	• 0116: Anti-platelet medication at discharge
	• 0118: Anti-lipid treatment
	• 0119: Risk-adjusted operative mortality for CABG
	• 0120: Risk-adjusted operative mortality for a ortic valve
	replacement (AVR)
	• 0121: Risk-adjusted operative mortality for mitral valve
	replacement

	• 0122: Risk-adjusted operative mortality MV replacement + CABG
	surgery
	• 0123: Risk-adjusted operative mortality for AVR + CABG
	• 0129: Risk-adjusted prolonged intubation (ventilation)
	 0130: Risk-adjusted deep sterna wound infection rate 0131: Risk-adjusted stroke/cerebrovascular accident
	 0131: Risk-adjusted stroke/cerebrovascular accident 0300: Cardiac patients with controlled 6 am postoperative serum
	glucose
	• 1501: Risk-adjusted operative mortality for MV repair
	• 1502: Risk-adjusted operative mortality for MV repair + CABG
	surgery
9:40 am	Discussion of Phase I Related/ Competing Measures and Steering Committee
	Recommendation for Endorsement
	• 0113: Participation in a systematic database for cardiac surgery
	• 0134: Coronary artery bypass graft (CABG) using internal mammary artery
	(IMA)
	• 0218: Surgery patients who received appropriate venous thromboembolism (VTE) prophylaxis within 24 hours prior to surgery to 24 hours after surgery
	end time
	 0360: Esophageal resection mortality rate (IQI 8) (risk adjusted)
	 0360: Esophageal resection mortanty rate (IQI 8) (IISK adjusted) 0361: Esophageal resection volume (IQI 1)
10:10 am	Consideration of Candidate Measures
10.10 am	Brief Introduction of Measures by Developer(s)
	Brief Introduction of Medsures by Developer(s)
10:25 am	Cardiac, Appendectomy and Pancreatic Resection
	• 0127: Pro operativo hata blockado
	 0127: Pre-operative beta blockade 0284: Surgery patients on beta blocker therapy prior to admission who
	• 0284: Surgery patients on beta blocker therapy prior to admission who received a beta blocker during the perioperative period
	 0117: Beta blockade at discharge
	 1480: Patient(s) 18 years of age and older on a beta-blocker at admission or
	within seven days of discharge of an isolated CABG
	within seven days of discharge of an isolated CADO
11:25 am	Break
11:40 am	Cardiac, Appendectomy and Pancreatic Resection (continued)
	• 0365: Pancreatic resection mortality rate (IQI 9) (risk adjusted)
	• 0366: Pancreatic resection volume (IQI 2)
	• 0273: Perforated appendix admission rate (PQI 2)
	• 0364: Incidental appendectomy in the elderly rate (IQI 24) (risk adjusted)
12:25 pm	NQF Member/Public Comment
12.40	Level Devel (level a second de d)
12:40 pm	Lunch Break (lunch provided)

1:10 pm	Cardiac, Appendectomy and Pancreatic Resection (continued)
	 0265: Hospital transfer/admission 1519: Statin therapy at discharge after lower extremity bypass (LEB)
1:30 pm	Cardiac and Vascular
	 0357: Abdominal aortic aneurysm volume (AAA) (IQI 4) 0359: Abdominal aortic artery (AAA) repair mortality rate (IQI 11) (risk adjusted) 1523: In-hospital mortality following elective open repair of small AAAs 1534: In-hospital mortality following elective EVAR of small AAAs 1548: Surveillance after endovascular abdominal aortic aneurysm repair (EVAR) 1540: Postoperative stroke or death in asymptomatic patients undergoing carotid endarterectomy 1543: Postoperative stroke or death in asymptomatic patients undergoing carotid artery stenting (CAS) 1531: Follow-up assessment of stroke or death after carotid revascularization
3:30 pm	Break
3:45 pm	General, Ophthalmology, Orthopedics and Pediatrics
	 0339: Pediatric heart surgery mortality (PDI 6) (risk adjusted) 0340: Pediatric heart surgery volume (PDI 7) 0352: Failure to rescue in-hospital mortality (risk adjusted) 0353: Failure to rescue 30-day mortality 0351: Death among surgical inpatients with serious, treatable complications (PSI 4) 0515: Ambulatory surgery patients with appropriate method of hair removal 0301: Surgery patients with appropriate hair removal 1550: Hospital-level risk-standardized complication rate (RSCR) following elective primary total hip arthroplasty (THA) and total knee arthroplasty (TKA) 1551: Hospital-level 30-day all-cause risk-standardized readmission rate (RSRR) following elective primary total hip arthroplasty (THA) and total knee arthroplasty (TKA)
5:45 pm	NQF Member/Public Comment
6:00 pm	Adjourn

<u>Day 2 – May 5</u>

9:00 am	Welcome, Recap of Day One Dr. Morris Dr. Torchiana
9:10 am	Consideration of Candidate Measures Brief Introduction of Measures by Developer(s)
9:35 am	General, Ophthalmology, Orthopedics and Pediatrics
	 1536: Cataracts: Improvement in patient's visual function within 90 days following cataract surgery 1549: Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery
10:00 am	Break
10:15 am	General, Prophylaxis and Wound Dehiscence
	 0528: Prophylactic antibiotic selection for surgical patients 0126: Selection of antibiotic prophylaxis for cardiac surgery patients 0128: Duration of prophylaxis for cardiac surgery patients 0125: Timing of antibiotic prophylaxis for cardiac surgery patients 0264: Prophylactic intravenous (IV) antibiotic timing 0527: Prophylactic antibiotic received within 1 hour prior to surgical incision SCIP-Inf-1 0529: Prophylactic antibiotics discontinued within 24 hours after surgery end time
12:15 pm	NQF Member/Public Comment
12:30 pm	Lunch Break (lunch provided)
1:00 pm	General, Prophylaxis and Wound Dehiscence (continued)
	 0367: Post operative wound dehiscence (PDI 11) (risk adjusted) 0368: Post operative wound dehiscence (PSI 14) (risk adjusted)
1:30 pm	Discussion of Phase II Related and Competing Measures
2:30 pm	Gaps to be Filled to More Fully Capture an Episode of Care
3:00 pm	NQF Member/Public Comment
3:15 pm	Next Steps/Timeline for Project

3:30 pm Adjourn